Gilead and Others HIV Drug Anticompetitive Agreements Complaint

February 5, 2020

Anticompetitive efforts in the field of pharmaceuticals have become more sophisticated in recent years. This antitrust class action concerns combination antiretroviral therapy (cART) regimen drugs used by patients with human immunodeficiency virus (HIV), a condition that can lead to Acquired Immunodeficiency Syndrome (AIDS) and death. The complaint alleges that a number of companies have conspired to maintain a monopoly in the market for cART regimen drugs by extending patent protection, delaying the entry of generics, and charging “anticompetitive prices” for the drugs.

Case Event File: cart_regimen_drugs_antitrust_complaint.pdf

Related to: Gilead and Others HIV Drug Anticompetitive Agreements Class Action